Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.

TitleImproved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.
Publication TypeJournal Article
Year of Publication2014
AuthorsWaller, EK, Logan, BR, Harris, WAC, Devine, SM, Porter, DL, Mineishi, S, McCarty, JM, Gonzalez, CE, Spitzer, TR, Krijanovski, OI, Linenberger, ML, Woolfrey, A, Howard, A, Wu, J, Confer, DL, Anasetti, C
JournalJ Clin Oncol
Volume32
Issue22
Pagination2365-72
Date Published2014 Aug 01
ISSN1527-7755
KeywordsAdolescent, Adult, Bone Marrow Transplantation, Child, Child, Preschool, Dendritic Cells, Female, Humans, Infant, Infant, Newborn, Leukemia, Male, Middle Aged, Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis, Survival Analysis, Survival Rate, T-Lymphocytes, Unrelated Donors, Young Adult
Abstract

PURPOSE: To characterize relationships between specific immune cell subsets in bone marrow (BM) or granulocyte colony-stimulating factor-mobilized peripheral blood (PB) stem cells collected from unrelated donors and clinical outcomes of patients undergoing transplantation in BMTCTN 0201.

PATIENTS AND METHODS: Fresh aliquots of 161 BM and 147 PB stem-cell allografts from North American donors randomly assigned to donate BM or PB stem cells and numbers of transplanted cells were correlated with overall survival (OS), relapse, and graft-versus-host disease (GvHD).

RESULTS: Patients with evaluable grafts were similar to all BMTCTN 0201 patients. The numbers of plasmacytoid dendritic cells (pDCs) and naïve T cells (Tns) in BM allografts were independently associated with OS in multivariable analyses including recipient and donor characteristics, such as human leukocyte antigen mismatch, age, and use of antithymocyte globulin. BM recipients of > median number of pDCs, naïve CD8(+) T cells (CD8Tns), or naïve CD4(+) T cells (CD4Tns) had better 3-year OS (pDCs, 56% v 35%; P = .025; CD8Tns, 56% v 37%; P = .012; CD4Tns, 55% v 37%; P = .009). Transplantation of more BM Tns was associated with less grade 3 to 4 acute GvHD but similar rates of relapse. Transplantation of more BM pDCs was associated with fewer deaths resulting from GvHD or from graft rejection. Analysis of PB grafts did not identify a donor cell subset significantly associated with OS, relapse, or GvHD.

CONCLUSION: Donor immune cells in BM but not PB stem-cell grafts were associated with survival after unrelated-donor allogeneic hematopoietic stem-cell transplantation. The biologic activity of donor immune cells in allogeneic transplantation varied between graft sources. Donor grafts with more BM-derived Tns and pDCs favorably regulated post-transplantation immunity in allogeneic hematopoietic stem-cell transplantation.

DOI10.1200/JCO.2013.54.4577
Alternate JournalJ Clin Oncol
PubMed ID24982459
PubMed Central IDPMC4180368
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069286 / HL / NHLBI NIH HHS / United States
R01 CA188523 / CA / NCI NIH HHS / United States
U01 HL069246 / HL / NHLBI NIH HHS / United States
U10 HL069301 / HL / NHLBI NIH HHS / United States
U10 HL069330 / HL / NHLBI NIH HHS / United States
U10 HL109137 / HL / NHLBI NIH HHS / United States
U10 HL109322 / HL / NHLBI NIH HHS / United States
U10HL069294 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
U10 HL069286 / HL / NHLBI NIH HHS / United States
U10 HL069246 / HL / NHLBI NIH HHS / United States
U10 HL108987 / HL / NHLBI NIH HHS / United States